Johnson & Johnson (NYSE:JNJ) is now one of the 15 Best Boring Dividend Stocks to Buy. JNJ plans to acquire Halda Therapeutics for $3.05 billion in cash to strengthen its oncology pipeline, focusing on solid tumors and prostate cancer. Halda’s pipeline includes HLD-0915, a prostate cancer therapy in development for various tumor types.

In the previous month, JNJ reported third-quarter revenue of $15.56 billion from its Innovative Medicine division, exceeding analysts’ expectations. The company is a global healthcare entity engaged in researching, developing, and producing pharmaceuticals and medical technologies. JNJ’s acquisition of Halda reinforces its position in the oncology sector.

While JNJ is a solid investment, certain AI stocks may offer greater upside potential with less downside risk. A free report on the best short-term AI stock could provide valuable insights for investors. JNJ’s acquisition of Halda Therapeutics reflects its strategic focus on expanding its oncology portfolio and driving growth in the healthcare sector.

Read more at Yahoo Finance: JNJ to Acquire Halda Therapeutics for $3.05 Billion to Boost Oncology Pipeline